Polyunsaturated Lipid Oxidation Products And

Total Page:16

File Type:pdf, Size:1020Kb

Polyunsaturated Lipid Oxidation Products And POLYUNSATURATED LIPID OXIDATION PRODUCTS AND THEIR BIOLOGICAL ACTIVITIES: SYNTHESIS, GENERATION, EFFECTS AND PROTECTION by YU-SHIUAN CHENG Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Thesis Advisors: Dr. Robert G. Salomon Department of Chemistry CASE WESTERN RESERVE UNIVERSITY May, 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Yu-Shiuan Cheng candidate for the degree of Doctor of Philosophy *. Committee Chair Dr. Michael G. Zagorski Committee Member Dr. Blanton S. Tolbert Committee Member Dr. Fu-Sen Liang Committee Member Dr. Masaru Miyagi Date of Defense March 25th, 2019 *We also certify that written approval has been obtained for any proprietary material contained therein. This thesis is dedicated to my parents and my sister. iii TABLE OF CONTENTS Table of Contents iv List of Schemes vii List of Tables x List of Figures xi Acknowledgements xvi List of Abbreviations and Acronyms xviii Abstract xxiv Polyunsaturated Lipid Oxidation Products and Their Biological Activities: Synthesis, Generation, Effects and Protection 1. Introduction 1 1.1 Reactive oxygen species and oxidative stress 2 1.2 Free radical-induced lipid peroxidation 4 1.3 Protein adducts of oxidatively truncated lipids 7 1.4 Levuglandins and their protein adducts 9 1.5 Light-induced damage in the retina 12 1.6 Age-related macular degeneration (AMD) 16 1.7 References 22 2. Total Synthesis Confirms the Molecular Structure Proposed for Oxidized Levuglandin D2 30 2.1 Background 31 iv 2.2 Results and Discussion 33 2.3 Conclusions 56 2.4 Experimental Procedures 57 2.5 References 74 3. Light-induced Generation and Toxicity of Docosahexaenoate-derived Oxidation Products in Retinal Pigmented Epithelial Cells 80 3.1 Background 81 3.2 Results 86 3.3 Discussion 107 3.4 Conclusions 120 3.5 Experimental Procedures 123 3.5 References 138 4. 4-Hydroxy-7-oxo-5-heptenoic Acid (HOHA) Lactone-Induced Oxidative Stress and Mitochondrial Dysfunction in Retinal Pigmented Epithelial Cells: Protection by a Carnosine Analogue, L-Histidyl Hydrazide 161 4.1 Background 162 4.2 Results 169 4.3 Discussion 186 4.4 Conclusions and Future Prospects 195 4.5 Experimental Procedures 197 v 4.6 References 211 Appendix 222 Bibliography 259 vi LIST OF SCHEMES Chapter 1 Scheme 1.1. Oxidative fragmentation of PUFA phospholipids produces γ-hydroxy-α,β-unsaturated aldehydes. 7 Scheme 1.2. The cyclooxygenase (COX) and radical-induced cyclooxygenation of arachidonate produces isoLGs. 10 Scheme 1.3. Metabolism of LGs: generation of protein adducts, crosslinks and oxidized metabolites 12 Scheme 1.4. Type I and Type II photosensitized oxidation reactions 14 Scheme 1.5. Class I and Class II photochemical damage 16 Chapter 2 Scheme 2.1. Generation and proposed structure of ox-LGD2 31 Scheme 2.2. Synthetic design for ox-LGD2 33 Scheme 2.3. Synthesis of the upper side chain precursor 34 Scheme 2.4. Concise total synthesis of ox-LGD2 36 Scheme 2.5. Model study for selective removal of tert-butyl groups 39 Scheme 2.6. γ-Isomer model study 42 Scheme 2.7. Rearrangment of ox-LGE2 51 Chapter 3 Scheme 3.1. The work-flow for an ARPE-19 cell light damage model 91 vii Chapter 4 Scheme 4.1. L-Histidyl hydrazide as an inhibitor of lipid peroxidation products formation. 193 viii LIST OF TABLES Chapter 2 Table 2.1. One-pot three-component coupling of alkyne 2.6 with cuprates and allylic halides 35 Table 2.2. One-pot three-component coupling of alkyne 2.6 with various vinyl cuprates to generate maleate 2.14 37 Table 2.3. Comparison of organocopper reagents for synthesis of 2.4 37 Table 2.4. Model study for the mono methylation of a maleic anhydride 40 Table 2.5. Generation of 2.1 and 2.2 by desilylation of 2.1p and 2.2p 43 Chapter 3 Table 3.1. Optimized mass spectrometer parameters, selected ions and collision energies for quantitation of the MitoClick product in ARPE-19 mitochondria-enriched cell lysate 129 Table 3.2. Workflow for Strata X-C spin column 1st SPE enrichment of HOHA/DHHA lactone-GSH derivatives from bovine retina extracts 133 Table 3.3. Workflow for Hypercarb 2nd SPE enrichment of HOHA/DHHA lactone-GSH derivatives from bovine retina extracts 133 Table 3.4. HPLC gradient for the determination of HOHA/DHHA lactone-GSH derivatives in light exposed bovine retina extract 134 Table 3.5. Optimized mass spectrometer parameters, MRM transitions and collision energies for quantitation of HOHA/DHHA lactone-GSH derivatives in bovine retina extract 135 ix Table 3.6. Workflow for Strata X-33u spin column SPE enrichment of HOHA/DHHA lactone-GSH derivatives from ARPE-19 extracellular medium 135 Table 3.7. HPLC gradient for the determination of HOHA/DHHA lactone-GSH derivatives in extracellular medium from light exposed ARPE-19 cells 136 Table 3.8. Optimized mass spectrometer parameters, selected ions and collision energies for quantitation of HOHA/DHHA lactone-GSH derivatives in ARPE-19 extracellular medium 136 x LIST OF FIGURES Chapter 1 Figure 1.1. Main sources of ROS production in cells 3 Figure 1.2. Lipid peroxidation pathways 5 Figure 1.3. Transmission of light in the human eye 13 Figure 1.4. Outer retina (photoreceptor and RPE) is susceptible to photooxidative damage. 15 Figure 1.5. Classification of AMD 17 Figure 1.6. The alternative complement pathway 20 Chapter 2 Figure 2.1. HPLC separation of three-component coupling products 2.4 and 2.4’ 38 Figure 2.2. HMBC (red) and NOESY (blue) correlations distinguishing the structures of 2.1p and 2.2p 42 1 Figure 2.3. Comparison of H NMR spectra of ox-LGD2 chemical shifts with CHD2CN resonance set at 1.90 ppm (A) at 500 MHz from total synthesis and (B) at 600 MHz from extraction of Gracilaria edulis 44 Figure 2.4. HMBC (red) and NOSEY (blue) correlations distinguishing the structures of 2.1, 2.2 and 2.2d 46 1 Figure 2.5. H NMR spectrum of the ox-LGD2 and ox-LGE2 mixture generated from the HF desilylation reaction 46 Figure 2.6. Evolution of ox-LGs in CD3CN: (Left) HPLC chromatograph; (Right) 1H NMR spectrum 48 1 6 Figure 2.7. H NMR spectrum of Δ -ox-LGE2 (2.2d) 49 xi Figure 2.8. HPLC chromatogram of ox-LGD2, two diastereomers of 6 ox-LGE2, and Δ -ox-LGE2 52 Figure 2.9. 1H NMR spectrum of peak 1 (Figure 2.8 HPLC chromatograph) collected at 44 min 53 Figure 2.10. HPLC chromatogram of ox-LGD2, minor diastereomer (b) of ox-LGE2 53 Chapter 3 Figure 3.1. Oxidative cleavage of DHA-PC delivers HOHA-PC. HOHA lactone is then released from bilayer phospholipid membranes by spontaneous intramolecular transesterifica- tion. Covalent adduction of HOHA-PC and HOHA lactone to primary amino groups of protein lysyl residues and phos- phatidyl ethanolamines (PE) produces CEP derivatives. 83 Figure 3.2. Time-course for the formation of HOHA lactone GSH derivatives 87 Figure 3.3. Photogeneration of HOHA-PC from DHA-PC is followed by release of HOHA lactone. HOHA lactone-GSH adduct is generated by glutathionylation of HOHA lactone. NADPH-dependent reduction of the HOHA lactone-GSH adduct delivers the reduced GSH adduct, DHHA lactone- GSH, that is also produced by RPE cells exposed to HOHA lactone, e.g., that may be released by oxidatively damaged photoreceptor cells. 88 Figure 3.4. Quantitative LC-MS/MS analysis of HOHA lactone GSH derivatives (HOHA lactone-GSH plus DHHA lactone-GSH) production induced in bovine retina extracts by light sources of various wavelengths 89 Figure 3.5. Internalization of A2E: representative images showing green A2E autofluorescence in ARPE-19 cells preloaded for 24 h with A2E 91 Figure 3.6. Generation of DHHA lactone-GSH upon exposure to black light (Panel A), blue light (Panel B) or white light (Panel C) in ARPE-19 cells (A2E(-)) pre-incubated with 50 μg/mL DHA for 48 h or cells (A2E(+)) pre-incubated with DHA xii for 48 h followed by 10 μM A2E for 24 h with 24 h recovery in basal medium 93 Figure 3.7. Quantitation of GSH levels remaining in DHA/A2E-laden ARPE-19 cells 10 min (Panel A) or 24 h (Panel B) after irradiation for various times from 0 to 60 min 94 Figure 3.8. Generation of CEP in ARPE-19 cells after 20 min exposure to blue light 96 Figure 3.9. Measurement of mitochondrial membrane potential in light exposed DHA-rich A2E-laden ARPE-19 cells 98 Figure 3.10. Measurement of cell viability by MTT assay 24 h after exposure of A2E-laden ARPE-19 cells to blue light (430 nm) for 0 to 60 min 99 Figure 3.11. Measurement of mitochondrial membrane potential changes in ARPE-19 cells upon exposure to HOHA lactone 100 Figure 3.12. Measurement of the cell viability of ARPE-19 cells after exposure to 0 to 40 μM HOHA lactone for 24 h assessed by MTT assay (Panel A) and by Alamar Blue assay (Panel B) 101 Figure 3.13. Senescence of ARPE-19 cells exposed to HOHA lactone 103 Figure 3.14. Lysosomal membrane perturbation in ARPE-19 cells after incubation with HOHA lactone 105 Figure 3.15. Generation of CEP in ARPE-19 cells upon exposure to HOHA lactone 106 Figure 3.16. Postulated synergistic contributions of A2E and a family of α,β-unsaturated aldehyde products of lipid oxidative cleavage to light-induced apoptosis of RPE cells 118 Chapter 4 Figure 4.1.
Recommended publications
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Hypertensive Crises 8.25
    Hypertensive Crises 8.25 Hypertension crises secondary to monoamine oxidase inhibitor–tyramine interactions Monoamine oxidase inhibitor therapy Impaired degradation of intracellular amines Ingestion of (epinephrine, norepinephrine, dopamine) tyramine-containing food Accumulation of catecholamines in Hepatic monamine nerve terminal storage granules oxidase inhibition with decreased Increased circulating oxidative metabolism tyramine level of tyramine Massive release of catecholamines Tachyarrhythmias Vasoconstriction (increased systemic vascular resistance) Severe paroxysm of hypertension Hypertensive encephalopathy Acute hypertensive heart failure with pulmonary edema Intracerebral hemorrhage (Fig. 8-21) (Figs. 8-24 and 8-25) FIGURE 8-32 Hypertensive crises secondary to monoamine oxidase inhibitor–tyramine interactions. Severe paroxysmal hypertension complicated by intracerebral or subarachnoid hemorrhage, hypertensive encephalopathy, or acute hypertensive heart failure can occur in patients treated with monoamine oxidase (MOA) inhibitors after ingestion of certain drugs or tyramine- containing foods [48,49]. Because MAO is required for degradation of intracellular amines, including epinephrine, norepinephrine, and dopamine, MAO inhibitors lead to accumulation of catecholamines within storage granules in nerve terminals. The amino acid tyramine is a potent inducer of neurotransmitter release from nerve terminals. As a result of inhibition of hepatic MAO, ingested tyramine escapes oxidative degradation in the liver. In addition, the high circulating levels of tyramine provoke massive catecholamine release from nerve terminals, resulting in vasoconstriction and a paroxysm of severe hypertension. A hyper- adrenergic syndrome resembling pheochromocytoma then ensues. Symptoms include severe pounding headache, flushing or pallor, profuse diaphoresis, nausea, vomiting, and extreme prostration. The mean increase in blood pressure is 55 mm Hg systolic and 30 mm Hg diastolic [49]. The duration of the attacks varies from 10 minutes to 6 hours.
    [Show full text]
  • LF-117708-01 Hydralazine 20Mg-Ml Injection V7
    Package leaflet: Information for the patient 28055763 syringe, this is called an intravenous injection or; • A restriction of movement in part of the intestine; LF-117708-01 - it may be diluted further and injected very slowly • A deficiency of certain white blood cells which into your vein through a drip (intravenous infusion). can result in fever and ulceration of the mouth The recommended dose is 5 to 10 mg by and throat; intravenous injection, and will be repeated if • An increased number of white blood cells; necessary after 20 to 30 minutes. • Enlargement of the spleen; Hydralazine 20mg Powder for Concentrate for Solution for Injection/Infusion • A reduction in the number of red and white blood Your blood pressure will be taken whilst you cells and platelets in the blood; Hydralazine hydrochloride are receiving treatment and the dose adjusted • Depression; to make sure that you have gradual fall in your Read all of this leaflet carefully before you start • have been told you are a slow acetylator • Seeing or hearing things which are not really blood pressure to normal levels. taking this medicine because it (this means that your body handles some there (hallucinations); contains important information for you medicines more slowly than other people); If you are given more medicine than you should • Inflammation of the nerves which may cause weakness - Keep this leaflet. You may need to read it again. • suffer from any serious liver or kidney problems; As this medicine is given to you in hospital it is very or numbness especially in your fingers and toes; - If you have any further questions ask your • have blockage of one or more arteries that supply unlikely that an overdose will happen.
    [Show full text]
  • Toxicological Profile for Hydrazines. US Department Of
    TOXICOLOGICAL PROFILE FOR HYDRAZINES U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry September 1997 HYDRAZINES ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. HYDRAZINES iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 HYDRAZINES vii CONTRIBUTORS CHEMICAL MANAGER(S)/AUTHOR(S): Gangadhar Choudhary, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA Hugh IIansen, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA Steve Donkin, Ph.D. Sciences International, Inc., Alexandria, VA Mr. Christopher Kirman Life Systems, Inc., Cleveland, OH THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 1 . Green Border Review. Green Border review assures the consistency with ATSDR policy. 2 . Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points. 3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs. HYDRAZINES ix PEER REVIEW A peer review panel was assembled for hydrazines. The panel consisted of the following members: 1. Dr.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Hydralazine Hydrochloride Tablets, USP8073301/1120Rx Only
    HYDRALAZINE HYDROCHLORIDE- hydralazine hydrochloride tablet, film coated American Health Packaging ---------- Hydralazine Hydrochloride Tablets, USP 8073301/1120 Rx only DESCRIPTION HydrALAZINE hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is: HydrALAZINE hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition, and has a molecular weight of 196.64. Each tablet for oral administration contains 10 mg, 25 mg, 50 mg, or 100 mg hydrALAZINE hydrochloride, USP. Tablets also contain FD&C Red #40/Allura Red AC Aluminum Lake, hypromellose, lactose anhydrous, light mineral oil, microcrystalline cellulose, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, and titanium dioxide. CLINICAL PHARMACOLOGY Although the precise mechanism of action of hydrALAZINE is not fully understood, the major effects are on the cardiovascular system. HydrALAZINE apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. HydrALAZINE, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state. The peripheral vasodilating effect of hydrALAZINE results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral vascular resistance; and an increased heart rate, stroke volume, and cardiac output. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output. HydrALAZINE usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge.
    [Show full text]
  • Drugs Associated with an Increased Falls Risk
    DRUGS ASSOCIATED WITH INCREASED FALL RISK Beverly Hospital PSYCHOTROPICS PSYCHOTROPICS ANTIHYPERTENSIVES NARCOTICS Antidepressants Antipsychotics(Atypical) ACE Inhibitors Acetaminophen-Codeine- Citalopram (Celexa) Clozapine (Clozaril) Benazepril (Lotensin) Caffeine (Tylenol # 1/2/3) Fluoxetine (Prozac) Olanzapine (Zyprexa) Captopril (Capoter) Codeine Fluvoxamine (Luvox) Quetiapine (Seroquel) Perindopril (Coversy) Fentanyl (Sublimaze, Duragesi) Paroxetine (Paxit) Antipsychotics(Neuroleptics) Cilazapril (Inhibace) Hydromorphone (Dilaudid, Sentraline (Zoloft) Chiorpromazine (Largactil) Enalapril (Vasotec) Hydromorph Contin) Venlafaxine (Effexor) Haloperidol (Haldol) Ramipril (Altace) Meperidine (Demerol) Amitriptyline (Elavil) Hydroxyzine (Atarax) Lisinopril (Prinivil, Zestril) Morphine (MOS, MS Contin, Bupropion (Wellbutrin) Lithium Quinapril (Accupril) M-Eston) Clomipramine (Anafranit) Loxapine (Loxapac) Fosinopril (Monopril) Oxycodone (Percocel, Desipramine (Norpramin) Methotrimeprazine (Nozinan Beta Blockers Percodan, OxyContin) Doxepin (Sinequan) Perphenazine (Trilafon) Acebutolo (Sectrail) Pentazocine (Talwin) Imipramine (Tofranit) Prochlorperazine (Stemetil) Atenolol (Tenormin) Note: May be administered with Mirtazapine (Remeron) Risperidone (Resperdal) Bisoprolol (Monocor) dimenhydrinate (Gravol) or Moclobemide (Manerix) Thioridazine (Mellaril) Carvedilol (Coreg) prochlorperazine (Stemeo) which may increase side effects of drowsiness and Nortriptyline (Aventy) Trifluoperazine (Stelazine) Labetalol (Trandate) dizziness. Trazodone
    [Show full text]
  • Prescribed Drugs Containing Nitrogen Heterocycles: an Overview Cite This: RSC Adv., 2020, 10, 44247 Majid M
    RSC Advances View Article Online REVIEW View Journal | View Issue Prescribed drugs containing nitrogen heterocycles: an overview Cite this: RSC Adv., 2020, 10, 44247 Majid M. Heravi * and Vahideh Zadsirjan Heteroatoms as well as heterocyclic scaffolds are frequently present as the common cores in a plethora of active pharmaceuticals natural products. Statistically, more than 85% of all biologically active compounds are heterocycles or comprise a heterocycle and most frequently, nitrogen heterocycles as a backbone in their complex structures. These facts disclose and emphasize the vital role of heterocycles in modern drug design and drug discovery. In this review, we try to present a comprehensive overview of top Received 28th October 2020 prescribed drugs containing nitrogen heterocycles, describing their pharmacological properties, medical Accepted 23rd November 2020 applications and their selected synthetic pathways. It is worth mentioning that the reported examples are DOI: 10.1039/d0ra09198g actually limited to current top selling drugs, being or containing N-heterocycles and their synthetic rsc.li/rsc-advances information has been extracted from both scientific journals and the wider patent literature. Creative Commons Attribution 3.0 Unported Licence. 1. Introduction chloroquinine, azidothymidine and anti-pyrine. Furthermore, most of the vitamins, nucleic acid, enzymes, co-enzymes, hormones, and 13 Medicinal and pharmaceutical chemistry are disciplines at the alkaloids contain N-based heterocycles as scaffolds. intersection of chemistry, especially synthetic organic chemistry, and Due to exhibiting diverse biological activities, nitrogen pharmacology and various other biological specialties, leading to the heterocyclic compounds have always been attractive targets to design, chemical synthesis and development of bio-active molecules, synthetic organic chemists.
    [Show full text]
  • Hydralazine 25Mg and 50Mg Tablets
    Package leaflet: Information for the patient Hydralazine 25mg and 50mg tablets Read all of this leaflet carefully • have angina pectoris, which causes pain in the chest before you start taking this with exercise medicine because it contains • have cerebrovascular disease (narrowing of the blood vessels in the brain) important information for you. • have been told you are a slow acetylator (this means • Keep this leaflet. You may need to that your body handles some medicines more slowly read it again. than other people) • If you have any further questions, • suffer from any serious liver or kidney problems. ask your doctor or pharmacist. Tests • This medicine has been prescribed If you are taking long-term Hydralazine treatment, for you only. Do not pass it on to your doctor may want to carry out blood and urine others. It may harm them, even if tests every 6 months. their signs of illness are the same as yours. Other medicines and Hydralazine tablets • If you get any side effects, talk to Tell your doctor or pharmacist if you are taking, have your doctor or pharmacist. This recently taken or might take any other medicines. includes any possible side effects It is especially important to tell your doctor if you are not listed in this leaflet. See section taking: 4. • medicines for high blood pressure, such as vasodilators (e.g. minoxidil diazoxide) What is in this leaflet • ACE inhibitors (e.g. enalapril, lisinopril, captopril) • Beta-blockers (e.g. propranolol) 1 What Hydralazine tablets are • calcium antagonists (e.g. nifedipine or diltiazem) and what they are used for • medicines for water retention (e.g.
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]